See-thru value: Why HTAs must show true drug benefit
This article was originally published in Scrip
Executive Summary
News that NICE is to be responsible for conducting the "full value assessment" in the UK's future value-based pricing system has again raised questions about the nature of "value" where medicines are concerned.